Clinical Communications
Mepolizumab for allergic bronchopulmonary aspergillosis: Report of 20 cases from the Belgian Severe Asthma Registry and review of the literature

https://doi.org/10.1016/j.jaip.2020.03.023Get rights and content

First page preview

First page preview
Click to open first page preview

References (10)

There are more references available in the full text version of this article.

Cited by (26)

  • Biologics for severe asthma and beyond

    2023, Pharmacology and Therapeutics
  • Treatments of refractory eosinophilic lung diseases with biologics

    2023, Allergology International
    Citation Excerpt :

    The expected effects of biologics on ABPA patients are as follows: reducing the ABPA exacerbation rate, improving clinical symptoms (including uncontrolled asthma) and radiographic findings, reducing the maintenance dose of OCS, and treating patients unable to receive standard treatment. Case reports, case series, small RCTs have demonstrated the efficacy and safety of omalizumab,44–49 mepolizumab,50–57 benralizumab,58–60 and dupilumab.61–65 Table 3 demonstrates case series studies including 5 or more cases of ABPA/ABPM treated with biologics.

View all citing articles on Scopus

The BSAR website is supported by unrestricted grants from Novartis, GSK, Chiesi, Boehringer, Astrazeneca, Teva and Sanofi.

Conflicts of interest: The authors declare that they have no relevant conflicts of interest.

View full text